SP-13786
(Synonyms: (S)-N-[2-(2-氰基-4,4-二氟-1-吡咯烷基)-2-氧代乙基]喹啉-4-甲酰胺) 目录号 : GC19425
SP-13786是一种强效、高选择性的成纤维细胞活化蛋白（FAP）和脯氨酰寡肽酶（PREP）抑制剂（FAP: IC50 = 3.2nM; PREP: IC50 = 1.8μM)。
Cas No.:1448440-52-5
Sample solution is provided at 25 µL, 10mM.
SP-13786 is a potent and highly selective inhibitor of fibroblast activation protein (FAP) and prolyl oligopeptidase (PREP) (FAP: IC50 = 3.2nM; PREP: IC50 = 1.8μM) [1]. SP-13786 inhibits FAP's serine protease activity by binding to its catalytic site, thereby inhibiting FAP's function in tumor stroma or fibrotic tissue [2]. SP-13786 is used to study the role of FAP in tumors, fibrosis, and other pathological processes [3-4].
In MGC803 cells, Co-incubation with SP-13786 (10μM; 24h) significantly reduced the antitumor activity of cresyl violet (CV)-FAP [5]. In U87MG-Fluc cells, SP-13786 (50μM, 100μM; 30min) reduces intracellular FAP levels [6].
In BALB/c mice, SP-13786 (10mg/kg; iv; signle injection) targets and inhibits FAPα activity [7]. In myocardial infarction (MI) mouse model, SP-13786 (0.5mg/kg; ip; 7d) inhibits FAP and significantly improves cardiac function and promotes angiogenesis after MI [8].
References:
[1]. Jansen K, Heirbaut L, Verkerk R, et al. Extended structure–activity relationship and pharmacokinetic investigation of (4-quinolinoyl) glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)[J]. Journal of medicinal chemistry, 2014, 57(7): 3053-3074.
[2]. Kiani M, Jokar S, Hassanzadeh L, et al. Recent clinical implications of FAPI: imaging and therapy[J]. Clinical nuclear medicine, 2022: 10.1097.
[3]. Butuzova D A, Kulebyakina M A, Basalova N A, et al. Fibroblast Activation Protein Alpha (FAPα) as a Promising Target in the Diagnostics and Treatment of Cancer and Fibrotic Diseases: Recent Approaches to Imaging and Assessment of Functional Activity[J]. Biochemistry (Moscow), 2025, 90(Suppl 1): S135-S145.
[4]. Zhou Y, Yin K, Dong H, et al. Long-lasting bioluminescence imaging of the fibroblast activation protein by an amphiphilic block copolymer-based probe[J]. Analytical Chemistry, 2021, 93(8): 3726-3732.
[5]. Liu S Y, Wang H, Nie G. Ultrasensitive fibroblast activation protein-α-activated fluorogenic probe enables selective imaging and killing of melanoma in vivo[J]. ACS sensors, 2022, 7(7): 1837-1846.
[6]. Lin Y, Ma Z, Li Z, et al. Bioluminescent probe for monitoring endogenous fibroblast activation protein-alpha[J]. Analytical Chemistry, 2019, 91(23): 14873-14878.
[7]. Fu A, Wang H, Huo T, et al. A novel chemiluminescence probe for sensitive detection of fibroblast activation protein-alpha in vitro and in living systems[J]. Analytical Chemistry, 2021, 93(16): 6501-6507.
[8]. Sun Y, Ma M, Cao D, et al. Inhibition of fap promotes cardiac repair by stabilizing BNP[J]. Circulation research, 2023, 132(5): 586-600.
SP-13786是一种强效、高选择性的成纤维细胞活化蛋白（FAP）和脯氨酰寡肽酶（PREP）抑制剂（FAP: IC50 = 3.2nM; PREP: IC50 = 1.8μM) [1]。SP-13786通过结合FAP的催化位点抑制其丝氨酸蛋白酶活性，从而抑制FAP在肿瘤基质或纤维化组织中的功能 [2]。SP-13786用于研究FAP在肿瘤、纤维化和其他病理过程中的作用 [3-4]。
在MGC803细胞中，与SP-13786（10μM；24h）共孵育可显著降低甲酚紫（CV）-FAP的抗肿瘤活性 [5]。在U87MG-Fluc细胞中，SP-13786（50μM，100μM；30min）可降低细胞内FAP水平 [6]。
在BALB/c小鼠中，SP-13786（10mg/kg；iv；单次注射）靶向抑制FAPα活性 [7]。在心肌梗死（MI）小鼠模型中，SP-13786（0.5mg/kg；ip；7d）可抑制FAP，显著改善心肌功能，并促进心肌梗死后的血管生成 [8]。
| Cell experiment [1]: | |
Cell lines | MGC803 cells |
Preparation Method | For cell cytotoxicity assay, cells were previously seeded on 96-well plates at a density of 1 × 104 per well in 200μL of culture medium; after 16h, the culture medium was removed, and fresh serum-free culture medium containing different dosages of cresyl violet (CV)-FAP, cresyl violet, or SP-13786 together with CV-FAP was added. After incubation for 24h, 20μL of cell counting kit-8 (CCK-8) was added to each well and incubated at 37℃ for 2h; the absorbance intensity at 450nm was recorded using a multifunctional microplate reader. |
Reaction Conditions | 10μM; 24h |
Applications | Co-incubation with SP-13786 significantly reduced the antitumor activity of CV-FAP. |
| Animal experiment [2]: | |
Animal models | BALB/c mice |
Preparation Method | BALB/c mice were divided into two groups randomly and anesthetized with 3% isoflurane in 97% oxygen gas. To estimate the distribution and clearance of probe CFCL and the inhibition effect of SP-13786 on FAPα in the whole animal level, the mice were treated with probe CFCL intravenously (200μM, 100μL) with or without the pretreating of SP-13786 in saline (10mg/kg, i.v.). The images of each mouse were recorded with 1min exposure time. |
Dosage form | 10mg/kg; iv; signle injection |
Applications | SP-13786 targets and inhibits FAPα activity. |
References: | |
| Cas No. | 1448440-52-5 | SDF | |
| 别名 | (S)-N-[2-(2-氰基-4,4-二氟-1-吡咯烷基)-2-氧代乙基]喹啉-4-甲酰胺 | ||
| Canonical SMILES | O=C(C1=CC=NC2=CC=CC=C12)NCC(N3[C@H](C#N)CC(F)(F)C3)=O | ||
| 分子式 | C17H14F2N4O2 | 分子量 | 344.32 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL |
| 5 mM | 580.9 μL | 2.9043 mL | 5.8086 mL |
| 10 mM | 290.4 μL | 1.4521 mL | 2.9043 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet